Utah Study Validates That Selective Serotonin Reuptake Inhibitors (SSRIs) Such As Fluoxetine Or Fluvoxamine Do Not Reduce COVID Severity
Source: COVID-19 Drugs - Fluvoxamine Nov 07, 2022 2 years, 2 weeks, 2 days, 6 hours, 33 minutes ago
COVID-19 Drugs: A new study by researchers from Intermountain Medical Center; Stanford, Salt Lake City-Utah, USA has confirmed that the usage of selective serotonin reuptake inhibitors (SSRIs) such as Fluoxetine or Fluvoxamine does not reduce COVID Severity.
Shockingly, the study findings showed that hospitalization and death were significantly greater in the those taking SSRIs such as Fluoxetine or Fluvoxamine compared to those who did not take them!
.jpg)
The usage of selective serotonin reuptake inhibitors (SSRI), the most commonly prescribed class of antidepressants was initially promoted by a few charlatan doctors on the basis that the drug did have certain anti-inflammatory and anti-platelet effects.
Thailand
Medical News had already warned many times that people exposed to the SARS-CoV-2 virus already have increased risk of heart issues and such selective serotonin reuptake inhibitors (SSRI) as Fluoxetine Or Fluvoxamine can also increase heart issues and contribute to the risk of mortality from heart failures in such individuals!
https://www.thailandmedical.news/news/most-who-have-been-exposed-to-the-proteins-of-the-sars-cov-2-virus-will-have-shortened-lifespans-stop-using-fluvoxamine-for-ba-2-infections
https://www.thailandmedical.news/news/world-health-organization-issues-warning-against-the-use-of-fluvoxamine-and-colchicine-to-treat-covid-19
Certain groups even tried to get the US FDA to approve SSRIs specifically fluoxetine/fluvoxamine to treat COVID-19 but fortunately it was rejected on grounds of insufficient data.
The
COVID-19 Drugs study team from Utah studied patients (n=33,088) testing positive for SARS-CoV-2 between March 14, 2020-December 31, 2021 as outpatients.
Studied patients were matched 3:1 by SSRI prescription at the time of a positive test by propensity score (±0.001). Patients were evaluated for COVID-19 hospitalization within 14-days and death within 3-months of positive SARS-CoV-2 test.
A total of 8,272 SSRI patients were well-matched to 24,816 no SSRI patients.
Shockingly, the study findings showed that hospitalization and death were significantly greater in the SSRI group compared to the no SSRI group.
This Thailand
Medical News attributes to our claims that these drugs induce heart issues and also aggravates the heart issues caused by the SARS-CoV-2, increasing the risk for fatal outcomes.
A total of 2,067 (25.0%) of SSRI patients were taking fluoxetine or fluvoxamine. While attenuated, no SSRI remained associated with a lower 14-day COVID-19 hospitalization risk when compared to fluoxetine or fluvoxamine use, but not with 3-month
death.
The study findings did not show a lower risk of progression of COVID-19 severity with the use of any SSRI or fluoxetine/fluvoxamine alone.
These study findings support the U.S FDA’s decision to not recommend their use at an early stage of a COVID-19 infection.
The study findings were published as an abstract presentation in the peer reviewed journal: Circulation (A journal of the American Heart Association or AHA)
https://www.ahajournals.org/doi/abs/10.1161/circ.146.suppl_1.10842
The study findings by the researchers at Intermountain Healthcare in Salt Lake City validates that the most commonly prescribed class of anti-depressants does not help reduce the severity of illness or even death for individuals who get COVID.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressants in America and are also available in many states and across the borders and online stores as a cheap OTC drug.
Though these drugs do have both anti-inflammatory and anti-platelet effects, they do not help in any way in COVID-19 infections and are in fact dangerous due to their possible effects on the heart.
Dr Heidi T. May, Ph.D., principal investigator of the study and cardiovascular epidemiologist with the Intermountain Healthcare Heart and Vascular Program warned, "At the start of the pandemic, everyone was searching for how to help prevent severe COVID, and SSRIs became a focus of interest. However, those initial observations of a possible connection didn't pan out when we looked for a possible link on our patient population."
The study findings from the study were presented at the American Heart Association's Scientific Sessions 2022, which is being held in Chicago.
https://exhibitatsessions.org/scientific-sessions/#:~:text=AHA's%20Scientific%20Sessions%202022%20will,reaching%20a%20simultaneous%20virtual%20audience!
For this retrospective study, the researchers from Intermountain Healthcare examined 33,088 individuals who tested positive for COVID-19 between March 14, 2020, and December 31, 2021, in an Intermountain outpatient setting. Of those individuals, 8,272 were also on a fluoxetine/fluvoxamine SSRI.
The study team worryingly found that hospitalization and death were significantly greater in the SSRI group than the non-SSRI group, and that not being on an SSRI was associated with a lower 14-day COVID-19 hospitalization risk.
The study findings confirm that serotonin reuptake inhibitors (SSRIs) such as Fluoxetine or Fluvoxamine does not reduce COVID Severity and I fact can aggravate the condition.
The study team warned, "These results add to the body of research that the relationship that, for patients testing positive in an outpatient setting, SSRI medications didn't reduce the risk of their then-mild COVID turning into severe COVID, or dying of the virus.”
For the latest on
COVID-19 Drugs, keep on logging to Thailand Medical News.
Share
Tweet
Share
